Irving, Texas (RBC Life Sciences: OTCBB: RBCL ) — RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, has launched a new payment option that allows its North American independent Associates to receive their commissions faster.

Branded as the RBC Life Sciences ClearPay Solution, the payment plan automatically credits an Associate’s monthly commissions to a debit card that may be used for everyday purchases. The ClearPay Solution debit card carries the RBC Life Sciences logo and an image of the company’s award-winning OliViva super-antioxidant drink. The card provides Associates with the added convenience of managing and tracking business expenses.

“With the ClearPay Solution, our Associates will never have to wait for a commission check again,” said RBC Life Sciences Director of Sales, Kevin Young. “The debit card is convenient, it’s safe, and it’s an excellent way to manage and track business expenses. The card also is a perfect match with a new compensation plan we’re creating that will offer our Associates the best commission earnings potential in the industry.”

In the six months following the company’s push to build its domestic sales base, 2,000 new independent Associates have joined RBC Life Sciences—an approximately 20 percent increase in the number of Associates the company had on November 1, 2020.

RBC Life Sciences partnered with ProPay to launch the new Associate payment option. ProPay is the industry’s most-comprehensive provider of simple, safe and affordable merchant payment solutions. The Utah-based company recently has partnered with eBay to offer payment solutions for the auction site’s largest power sellers.

About RBC Life Sciences
RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com .

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange